RecruitingNCT06874231
Brain Connectivity Marker for Alzheimer's Disease
Clinical Application of a Brain Connectivity Marker for Early Detection of Alzheimer's Disease
Sponsor
Karolinska Institutet
Enrollment
120 participants
Start Date
Apr 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).
Eligibility
Min Age: 40 YearsMax Age: 85 Years
Inclusion Criteria15
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30.
- Absence of cognitive impairment.
- Memory problems reported by the participant/family member.
- Do not fulfill criteria for mild cognitive impairment or dementia.
- Must speak and understand Swedish.
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30.
- Impaired memory function.
- Do not fulfill criteria for dementia.
- Must speak and understand Swedish.
- Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28.
- Impaired memory function in addition to impaired executive abilities, language function, visuospatial ability and/or attention/psychomotor speed.
- Meet NINCDS-ADRDA and DSM-IV criteria for probable Alzheimer's disease.
- Must speak and understand Swedish.
- Must have abnormal spinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
Exclusion Criteria4
- Alcohol or drug abuse.
- Unstable somatic disease or organ failure.
- Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram.
- In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study.
Interventions
OTHERNeuroimaging
The investigators will collect imaging sequence, cognitive test scores, clinical data and biofluid samples
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06874231
Related Trials
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
NCT041233141 location
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
NCT071782101 location
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT066577689 locations